A Phase II trial is underway for Tefina, a testosterone-based treatment for female sexual dysfunction.
A Phase II trial is underway for Tefina, a testosterone-based treatment for female sexual dysfunction. Nicknamed “the female Viagra,” the drug is administered via a nasal spray two hours before sexual activity, and is believed to increase desire and stimulate blood flow to the sexual organs, making it appropriate for both women with low desire as well as women with difficulty climaxing.
One fertility specialist, Ric Gordon, said he believed that the drug was “exploiting” female sexuality, because it overlooked the reasons behind a low sexual drive. He maintained that “men use sex to de-stress and women need to be de-stressed to have sex,” and so by bringing this drug to market, more complicated emotional issues will be ignored
Online Poll
|
Online Survey
Please add your thoughts in the Comments section below.
Pioglitazone outperforms metformin in IVF for PCOS-related infertility
May 6th 2024A recent double-blind, randomized clinical trial revealed a higher clinical pregnancy rate with pioglitazone compared to metformin in polycystic ovarian syndrome patients undergoing in vitro fertilization, suggesting potential for improved outcomes.
Read More
In this episode of Pap Talk, Gloria Bachmann, MD, MSc, breaks down what it means to be a health care provider for incarcerated individuals, and explores the specific challenges women and their providers face during and after incarceration. Joined by sexual health expert Michael Krychman, MD, Bachmann also discusses trauma-informed care and how providers can get informed.
Listen
Reducing multifetal pregnancy through publicly funded IVF programs
April 26th 2024Learn how a mandatory elective single-embryo transfer policy in publicly funded in vitro fertilization programs significantly decreases multifetal pregnancy rates, offering insights into mitigating risks in assisted reproduction.
Read More